Concentrated Ownership and Corporate Control: Wallenberg ...
Olov Wiklund Wallenberg Laboratory Gothenburg Sweden
Transcript of Olov Wiklund Wallenberg Laboratory Gothenburg Sweden
![Page 1: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/1.jpg)
Olov Wiklund Wallenberg Laboratory
Gothenburg Sweden
![Page 2: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/2.jpg)
Declaration of Interest
Research collaboration with Astra-Zeneca
Educational acitivies together with Pfizer, Astra-Zeneca and MSD
![Page 3: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/3.jpg)
![Page 4: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/4.jpg)
![Page 5: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/5.jpg)
HDL - Triglycerides and CVD
![Page 6: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/6.jpg)
Cholesterol in atherogenic lipoproteins
![Page 7: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/7.jpg)
Non-HDL and CVD risk
![Page 8: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/8.jpg)
![Page 9: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/9.jpg)
![Page 10: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/10.jpg)
Conclusion
![Page 11: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/11.jpg)
![Page 12: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/12.jpg)
![Page 13: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/13.jpg)
![Page 14: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/14.jpg)
Mendelian randomisation suggest the Lp(a) is causal for CVD
Kamstrup et al., JAMA 2009; 301:2331
Clarke et al., N Engl j Med 2009; 361:2518
![Page 15: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/15.jpg)
![Page 16: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/16.jpg)
Other suggested lipid biomarkers
Small dense LDL
HDL subclasses
Genetic markers
OxLDL antibodies
Lipid oxidation products
LpPLA2
![Page 17: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/17.jpg)
![Page 18: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/18.jpg)
A combination of N-BNP, CRP and TROPONIN T could improve risk estimation on
top of other risk factors
![Page 19: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/19.jpg)
Hazard
ratio f
or
CV
D
CRP mg/ml
![Page 20: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/20.jpg)
CHD risk after correction for conventional risk factors
CRP, mg/ml
Basal correction Corrected for conventional
Risk factors
![Page 21: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/21.jpg)
CRP and non-vascular death
![Page 22: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/22.jpg)
Is CRP a tool to better identify high risk patients ?
![Page 23: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/23.jpg)
![Page 24: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/24.jpg)
CRP does not improve discrimination of high risk patients!!
![Page 25: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/25.jpg)
Conclusion from a meta-analysis
CRP does not perform better than the Framingham risk equation for discrimination.
The improvement in risk stratification or reclassification from addition of CRP to models based on established risk factors is small and inconsistent
Shah et al Int J Epidem 2009;38:217
![Page 26: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/26.jpg)
Using plaque composition to identify Biomarkers
![Page 27: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/27.jpg)
ApoAI in plasma is strongly correlated with
plaque stability
Serum apoAI (mg/ml)
2,01,81,61,41,21,0,8
Tis
su
e C
olla
ge
n (
% S
urf
ace
)
60
50
40
30
20
10
0
Serum apoAI (mg/ml)
2,01,81,61,41,21,0,8
Tis
su
e M
acro
ph
ag
es (
% S
urf
ace
)40
30
20
10
0
rs= -0.59, P < 0.01 rs= 0.64, P < 0.01
Solem et al., JIM, 2006
![Page 28: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/28.jpg)
Vascular event and osteopontin in plaques
D.P.V. de Kleijn et al., ATVB 2010, 30:612
![Page 29: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/29.jpg)
Biomarkers for future disease in CVD patients
![Page 30: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/30.jpg)
Inflammation and long term mortality in ACS patients
Hartford et al JIM, 2007
CRP IL-6
PLA2 ICAM-1
![Page 31: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/31.jpg)
![Page 32: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/32.jpg)
Biomarkers for CVD in TNT
None of the non-lipid biomarkers added possibility to predict future CVD
![Page 33: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/33.jpg)
CONCLUSION
In addition to conventional lipid biomarkers and other risk factors the contribution of new biomarkers is small.
Inflammation markers are the best documented of new potential biomarkers for CVD risk and atherosclerosis.
CRP could be considered especially in intermediate risk subjects.
![Page 34: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/34.jpg)
![Page 35: Olov Wiklund Wallenberg Laboratory Gothenburg Sweden](https://reader031.fdocuments.us/reader031/viewer/2022020704/61fb57cd2e268c58cd5d0c01/html5/thumbnails/35.jpg)
Criteria for evaluation of novel biomarkers Proof of concept
Prospective evaluation
Incremental value
Clinical utility
Clinical outcomes
Cost effectiveness